Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The envelope glycoprotein (GP) of Zaire ebolavirus is the sole viral protein expressed on the surface of the virion. It is essential for virus entry into host cells, mediating both attachment to cellular receptors and fusion between viral and host membranes. The GP exists as a trimeric complex composed of two subunits: GP1 and GP2, which are generated by post-translational proteolytic cleavage of a single precursor polypeptide. GP1 functions primarily in receptor binding and contains a glycan cap and mucin-like domain that shield conserved regions from immune recognition. GP2 is responsible for membrane fusion. Upon activation, it undergoes conformational changes exposing its hydrophobic fusion loop, facilitating merger with host membranes. It also downregulates expression of several host cell adhesion molecules (integrins), contributing to vascular leakage seen in Ebola hemorrhagic fever; also modulates immune responses by interacting with TLR4.
Neutralizing antibodies block conformational changes required for membrane fusion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zaire ebolavirus envelope glycoprotein (GP).